Published in Nat Commun on May 12, 2016
Design and Validation of Novel Chikungunya Virus Protease Inhibitors. Antimicrob Agents Chemother (2016) 0.78
Characterization of β-d-N(4)-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus. Antimicrob Agents Chemother (2017) 0.75
Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library. F1000Res (2016) 0.75
ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res (2011) 14.51
The druggable genome. Nat Rev Drug Discov (2002) 13.61
Identification of host proteins required for HIV infection through a functional genomic screen. Science (2008) 12.44
A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A (2000) 12.16
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science (2009) 10.30
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell (2008) 8.41
Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov (2004) 7.57
DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res (2013) 6.73
Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat Biotechnol (2008) 5.77
Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods (2014) 5.76
Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol (2011) 5.65
Human host factors required for influenza virus replication. Nature (2010) 5.28
Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med (2015) 5.16
RNA interference screen for human genes associated with West Nile virus infection. Nature (2008) 4.93
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe (2009) 4.24
Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature (2010) 4.23
Analysis of cell-based RNAi screens. Genome Biol (2006) 3.99
Discovery of insect and human dengue virus host factors. Nature (2009) 3.49
A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog (2008) 3.40
A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods (2007) 3.34
Characterization of reemerging chikungunya virus. PLoS Pathog (2007) 3.22
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci U S A (2010) 2.97
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis (2009) 2.54
Infectious disease. Combating emerging viral threats. Science (2015) 2.19
The design of drugs for HIV and HCV. Nat Rev Drug Discov (2007) 1.85
A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol (2010) 1.48
Development and characterization of a double subgenomic chikungunya virus infectious clone to express heterologous genes in Aedes aegypti mosquitoes. Insect Biochem Mol Biol (2005) 1.45
A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice. J Immunol (2012) 1.27
Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med (2012) 1.24
Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep (2011) 1.14
Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. PLoS Pathog (2014) 1.11
Curing a viral infection by targeting the host: the example of cyclophilin inhibitors. Antiviral Res (2013) 1.10
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer (2012) 1.05
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. Proc Natl Acad Sci U S A (2013) 1.04
Genome-wide RNAi screen identifies broadly-acting host factors that inhibit arbovirus infection. PLoS Pathog (2014) 1.03
An in vivo RNAi screening approach to identify host determinants of virus replication. Cell Host Microbe (2013) 1.01
Genome-wide RNAi screen identifies novel host proteins required for alphavirus entry. PLoS Pathog (2013) 0.99
Genome-wide RNAi screen identifies SEC61A and VCP as conserved regulators of Sindbis virus entry. Cell Rep (2013) 0.93
Magnetic fractionation and proteomic dissection of cellular organelles occupied by the late replication complexes of Semliki Forest virus. J Virol (2013) 0.89
Points of significance: two-factor designs. Nat Methods (2014) 0.87
Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout. Virol J (2013) 0.84
cSSMD: assessing collective activity for addressing off-target effects in genome-scale RNA interference screens. Bioinformatics (2011) 0.83
In vivo imaging of chikungunya virus in mice and Aedes mosquitoes using a Renilla luciferase clone. Vector Borne Zoonotic Dis (2011) 0.82
Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice. Exp Eye Res (2013) 0.81